Songlin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Songlin Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Heather Kleiner-Hancock
Department of Pharmacology, Toxicology & Neuroscience, Louisiana State University, Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
1 shared publication - Jonathan Glass
Feist-Weiller Cancer Center, Department of Medicine, LSU Health Sciences Center, Shreveport, Louisiana. 1501 Kings Highway, Shreveport, LA 71130, USA
1 shared publication - Misty Prince
Department of Pharmacology, Toxicology and Neuroscience, LSUHSC-S, Shreveport, Louisiana, USA
1 shared publication - Run-Hua Shi
North China Electric Power University
1 shared publication - Syed H Jafri
Department of Medicine, Division of Hematology/Oncology, Louisiana State University Health, Shreveport, LA, USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 87
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP).
- 1 July 2010
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 87
Open AccessThymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP).